Heme oxygenase-1 contributes to an alternative macrophage activation profile induced by apoptotic cell supernatants

Nicole Weis*, Andreas Weigert*, Andreas von Knethen* and Bernhard Brüne*

* Goethe-University, Institute of Biochemistry I/ZAFES, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany

Running head: HO-1 alternatively activates macrophages

Abbreviations:
AC, apoptotic cells; HO-1, Heme oxygenase-1; S1P, sphingosine-1-phosphate; VEGFA, vascular endothelial growth factor A; CO, carbon monoxide; S1P1, S1P-receptor 1; Adora A2A, adenosine receptor A2A; Jak, janus kinase; Deta-NO, diethylenetriamine-nitric oxide; CORM-2, tricarbonyldichloro ruthenium (II) dimer; CM, conditioned medium; NC, necrotic cells; VC, viable cells; DMS, dimethyl-sphingosine; IDO, indoleamine-2,3-dioxygenase; EMSA, electrophoretic mobility shift assay; МΦ-CM, macrophage CM; STATx, STAT response element; ptm, point mutation; TAMs, tumor associated macrophages

The work was supported by grants from Deutsche Forschungsgemeinschaft (Br 999, FOG 784, Excellence Cluster Cardiopulmonary System), Deutsche Krebshilfe, Sander Foundation, LOEWE program and European Community (PROLIGEN).
Corresponding author: Bernhard Brüne
Goethe-University
Institute of Biochemistry I/IZAFES
Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
Phone: +49-69-6301 7423
Fax: +49-69-6301 4203
e-mail: bruene@pathobiochemie1.de
ABSTRACT

Apoptotic cells (AC) are rapidly engulfed by professional phagocytes such as macrophages to avoid secondary necrosis and thus inflammation. Recognition of AC polarizes macrophages towards an anti-inflammatory phenotype, which shows homology to an alternatively activated M2 macrophage. However, mechanistic details provoking these phenotype alterations are incompletely understood. Here we demonstrate a biphasic up-regulation of heme oxygenase-1 (HO-1), a protein that bears an anti-apoptotic as well as an anti-inflammatory potential, in primary human macrophages, which were exposed to the supernatant of AC. While the first phase of HO-1 induction at 6 h was accomplished by AC-derived sphingosine-1-phosphate (S1P) acting via S1P receptor 1, the second wave of HO-1 induction at 24 h was attributed to autocrine signaling of vascular endothelial growth factor A (VEGFA), whose expression and release was facilitated by S1P. Whereas VEGFA release from macrophages was STAT1-dependent, VEGF itself triggered STAT1/STAT3 heterodimer formation, which bound to and activated the HO-1 promoter. Knockdown of HO-1 proved its relevance in facilitating enhanced expression of the anti-apoptotic proteins Bcl-2 and Bcl-X_L, as well as the anti-inflammatory adenosine receptor A2A. These findings suggest that HO-1, which is induced by AC-derived S1P, is critically involved in macrophage polarization towards an M2 phenotype.
INTRODUCTION

Macrophages, as innate immune competent cells, participate in a multitude of physiological as well as patho-physiological settings, which is a result of their extreme functional plasticity. Distinct forms of macrophage activation provoke a continuum of functional responses that range from pro- towards anti-inflammatory outcomes. Macrophages are classically activated by microbial cell wall components and/or IFN-γ. The resulting phenotype is known as M1, which is characterized among others parameters by the production of pro-inflammatory mediators such as NO, superoxide, TNF-α, IL-1β and IL-6 (Gordon, 2003). Polarization towards the alternatively activated phenotype (M2 macrophage) is achieved by e.g. glucocorticoids, IL-4, IL-13 or IL-10 (Mantovani et al., 2002; Gordon, 2003).

When cells enter the route of apoptotic cell death, phagocytosis of apoptotic debris by professional phagocytes such as macrophages avoids an inflammatory response (Rathmell and Thompson, 1999; Savill et al., 2002). During this process the interaction of apoptotic cells (AC) with macrophages actively suppresses the release of pro-inflammatory mediators and provokes the formation of anti-inflammatory ones. The mediator profile of these polarized macrophages resembles those of M2 cells, with the production of e.g. IL-10, TGF-β1 or PGE₂ (Voll et al., 1997; Fadok et al., 1998; Freire-de-Lima et al., 2000). Mechanisms attenuating pro-inflammatory signaling in macrophages by AC are at least in part attributed to defective LPS-induced NF-κB activation, and thus inhibition of pro-inflammatory cytokine gene expression profiles (Cvetanovic and Ucker, 2004).

In contrast, intracellular pathways activating anti-inflammatory responses are widely elusive. Recently, we observed that AC released the bioactive lipid sphingosine-1-
phosphate (S1P), which caused activation of survival pathways such as increased expression of the anti-apoptotic proteins Bcl-2 and Bcl-XL in human macrophages (Weigert et al., 2006). Although pioneering studies identified S1P as a second messenger molecule mediating cell proliferation of Swiss 3T3 fibroblasts (Olivera and Spiegel, 1993), S1P was later identified as the ligand for a family of five different G protein-coupled receptors (Hla et al., 2001; Taha et al., 2004). Activation of S1P receptors exerts a powerful influence on a variety of immune cells and their responses (von Wenckstern et al., 2006). Moreover, S1P provoked M2 macrophage polarization either when added directly to cells (Hughes et al., 2008), or when being present in the supernatant of AC (Weigert et al., 2007).

An ideal candidate that would fulfill requirements of acting anti-inflammatory as well as anti-apoptotic is heme oxygenase-1 (HO-1). HO-1 catalyzes the rate-limiting step in the oxidative degradation of heme to equimolar quantities of biliverdin, ferrous iron and carbon monoxide (CO). In contrast to HO-2 and HO-3, which are constitutively expressed, HO-1 is inducible and is well known to protect from cell death, i.e. apoptosis, inflammation and oxidative stress in vivo (Otterbein et al., 2000; Deshane et al., 2005; Kim et al., 2006). A connection between HO-1 induction and the S1P-pathway was recently established in a model of hepatic ischemia-reperfusion injury, where the S1P receptor agonist FTY720 enhanced HO-1 expression in hepatocytes (Man et al., 2005).
MATERIALS AND METHODS

Cell culture and reagents
Jurkat T cells were maintained in RPMI 1640, supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin and 10% heat-inactivated FCS (PAA Laboratories, Cölbe, Germany). SB203580 was obtained from Alexis (Lörrach, Germany), the Janus kinase (Jak) inhibitor I was purchased from Calbiochem (Darmstadt, Germany), S1P came from Avanti (Alabaster, AL, USA), fludarabine was obtained from Sigma-Aldrich (Steinheim, Germany), STA-21 was delivered by Biomol (Hamburg, Germany), Deta-N0, bilirubin and tricarbonyldichloro ruthenium (II) dimer (CORM-2) were obtained from Sigma-Aldrich (Steinheim, Germany). CORM-2 was freshly dissolved in DMSO for each experiment. As a negative control, CORM-2 was inactivated (iCORM-2) according to a previously described method (Sun et al., 2008). Trypan blue staining (Biochrom AG, Berlin, Germany) revealed that all used reagents were not toxic for macrophages.

Human monocyte isolation and culture
Human monocytes were isolated as described previously (Weigert et al., 2006). In brief, using Ficoll-Hypaque gradients (PAA Laboratories, Cölbe, Germany) monocytes were isolated from buffy coats (DRK-Blutspendedienst Baden-Württemberg-Hessen, Institut für Transfusionsmedizin und Immunhämatologie Frankfurt am Main, Frankfurt/Main, Germany). Peripheral blood mononuclear cells were washed twice with PBS containing 2 mM EDTA and subsequently incubated for 1 h at 37°C in RPMI 1640 supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin to allow their adherence to culture dishes (Sarstedt, Nümbrecht, Germany). After removing nonadherent cells, monocytes were differentiated to
macrophages with RPMI containing 10% ABpositive human plasma (DRK-Blutspendedienst Baden-Württemberg-Hessen, Institut für Transfusionsmedizin und Immunhämatologie Frankfurt am Main, Frankfurt/Main, Germany) for 7 days.

**Generation of conditioned media**

Apoptosis in Jurkat cells, cultured in RPMI 1640 without FCS, was induced with 0.5 µg/mL staurosporine (Sigma-Aldrich, Steinheim, Germany) for 3 h (Weigert *et al.*, 2006). Necrotic Jurkat cells were generated by incubating cells for 30 min at 56°C in RPMI 1640 with FCS (Weigert *et al.*, 2006). AC or necrotic cells (NC) were washed twice with PBS and incubated for another 3-h period in RPMI 1640 with 10% ABpositive human plasma. CM was harvested by centrifugation (1000 g, 10 minutes) and filtration through 0.22 µm pore filters (Millipore, Schwalbach, Germany) to remove apoptotic bodies. The procedure to generate CM from viable cells (VC) was equivalent. Jurkat cells were incubated in RPMI 1640 with FCS, omitting a death stimulus. To obtain AC-CM without S1P, we used 20 µM dimethylsphingosine (DMS, Biomol, Hamburg, Germany), an inhibitor of sphingosine kinases. DMS was added simultaneously with staurosporine to Jurkat cells during initiation of apoptosis (Weigert *et al.*, 2006). To generate macrophage CM (МΦ-CM), macrophages were incubated with AC-CM for 2 h, washed twice with PBS and incubated for another 4-h period in RPMI 1640 with 10% ABpositive human plasma. МΦ-CM was harvested by centrifugation (1000 g, 10 minutes). For protein degradation, МΦ-CM was incubated with 50 µg/mL proteinase K (Sigma-Aldrich, Steinheim, Germany) at 37°C for 1 h, followed by incubation at 100°C for 1 h. Cells were exposed to conditioned media for the times indicated. Inhibitors were pre-incubated for 1 h each. CM was generated using 1 x 10^7 Jurkat cells and later on added to 2 x 10^6 macrophages (ratio 5:1). МΦ-CM was directly transferred from generator to recipient cells.
**Western blot analysis**

Western blot analysis was performed as previously described (von Knethen et al., 2005). Polyclonal antibodies directed against HO-1 (Biomol, Hamburg, Germany), S1P1 (Orbigen, San Diego, CA, USA), Adora A2A (Calbiochem, Darmstadt, Germany), Bcl-XL (BD Transduction Laboratories, Lexington, KY, USA) and Actin (Sigma-Aldrich, Steinheim, Germany) were used. Western blots were quantified using Odyssey infrared imaging system (Li-Cor Biosciences, Bad Homburg, Germany).

**RNA extraction and quantitative real-time PCR**

RNA from primary human macrophages was extracted using peqGold RNAPure (Peqlab Biotechnologie GmbH, Erlangen, Germany). Total RNA (1 µg) was transcribed with iScript cDNA Synthesis Kit (Bio-Rad Laboratories, München, Germany). Quantitative real-time-PCR was performed using MyIQ real-time PCR system (Bio-Rad Laboratories, München, Germany) and Absolute Blue QPCR SYBR Green Fluorescein Mix (Thermo Scientific, Karlsruhe, Germany). The following primers (Biomers, Ulm, Germany) were used for quantitative real-time-PCR: human HO-1: 5’-GCC ACC AAG TTC AAG CAG CT-3’, 5’-CAG TGC CCA CGG TAA GGA AG-3’, human VEGF: 5’-TAC CTC CAC CAT GCC AAG TG-3’, 5’-AAG ATG TCC ACC AGG GTC TC-3’, human actin: 5’-TGA CGG GGT CAC CCA CAC TGT GCC CAT CTA-3’, 5’-CTA GAA GCA TTT GCG GTG GAC CAT GGA GGG-3’. For Bcl-2, Bcl-XL, Adora A2A, IDO, HLA-DMB and 18S RNA, validated QuantiTect Primer Assays were purchased from Qiagen (Hilden, Germany). Real-time PCR results were quantified using Gene Expression Macro (version 1.1) from Bio-Rad (München, Germany) with actin or 18S RNA expression as internal control.
**Reporter analysis**

Reporter assays were performed with vector constructs containing 4000 bp, 2782 bp or 1976 bp of the human HO-1 promoter fused to a firefly luciferase gene (Takahashi et al., 1999). The STAT3 point mutation was created with the Quik Change II Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). Experimentally, 10% of one buffy coat monocyte isolation preparation was seeded in one 12-well plate. After 7 days macrophages were co-transfected with HO-1 promoter constructs and renilla luciferase control vector pRL-CMV (Promega, Mannheim, Germany) using Jet Pei transfection reagent (Polyplus transfection, Illkirch, France). After transfection, cells were incubated for 24 h, medium was changed and cells were incubated for another 24 h followed by individual stimulation. Firefly luciferase activity normalized to renilla luciferase activity was determined after 18-h incubations with MΦ-CM or after 24 h following incubations with 100 nM S1P.

**Site-directed mutagenesis**

The online tool TFSearch (http://www.cbrc.jp/research/db/TFSEARCH.html) was used to identify potential STAT binding sites in the human HO-1 promoter (STATx). Quik Change II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) was used to introduce a point mutation of the putative STAT-binding site at position -2361 to -2369 within the human HO-1 promoter, in order to impair STAT3 binding. The following primers (Biomers, Ulm, Germany) were used to mutate the sequence from 5’-TTC CAG GAA-3’ to 5’-TTC CAG GCC-3’: 5’-CCA GGC ACT ATT CCA GGC CCT GGG AAT TTA CAA AGC-3’, 5’-GCT TTG TAA ATT CCC AGG GCC TGG AAT AGT GCC TGG-3’. Elongation was performed at 68°C for 15 min. Site-directed mutagenesis was confirmed by sequencing (Agowa, Berlin, Germany).
**Electrophoretic Mobility Shift Assay**

Nuclear extracts were prepared as previously described (Von Knethen and Brune, 2001) and an established electrophoretic mobility shift assay (EMSA) method (Weigert et al., 2007) was used. Briefly, 10 µg of nuclear protein were incubated for 30 min at room temperature with 2 µg poly (dl-dC) from Amersham Biosciences (Freiburg, Germany), 2 µl buffer D (20 mM HEPES/KOH, 20% glycerol, 100 mM KCl, 0.5 mM EDTA, 0.25% Nonidet P-40, 2 mM DTT, 0.5 mM PMSF, pH 7.9), 4 µl buffer F (20% Ficoll-400, 100 mM HEPES/KOH, 300 mM KCl, 10 mM DTT, 0.5 mM PMSF, pH 7.9), 250 fmol 5'-IRD700-labeled oligonucleotide (Metabion, Planegg-Martinsried, Germany) and in the case of competitive EMSA in addition with 2500 fmol or 25000 fmol unlabeled oligonucleotide in a final volume of 20 µl. Afterwards samples were incubated on ice for 5 min. DNA-protein complexes were resolved on native 6% polyacrylamide gels and analyzed with Odyssey infrared imaging system (Li-Cor, Bad Homburg, Germany). Oligonucleotides including the sequence of the putative STAT-binding site at -2361 to -2369 of the human HO-1 promoter were used: 5'-IRD700-AGG CAC TAT TCC AGG AAC TGG GAA T-3'; 5'-IRD700-ATT CCC AGT TCC TGG AAT AGT GCC T-3'. For competitive EMSA additional unlabeled oligonucleotides specific for STAT1 and STAT3 were used (Biomers, Ulm, Germany). STAT1: 5'-CAT GTT ATG CAT ATT CCT GTA AGT-3', 5'-ACT TAC AGG AAT ATG CAT AAC ATG-3'. STAT3: 5'-GAT CCT TCT GGG AAT TCC TAG ATC-3' 5'-GAT CTA GGA ATT CCC AGA AGG ATC-3'. Competitive EMSA was also performed with unlabeled oligonucleotides including the sequence of the putative STAT-binding site at -2361 to -2369, which included a point-mutation to impair STAT3 binding (bold): 5'-AGG CAC TAT TCC AGG CCC TGG GAA T-3'; 5'-ATT CCC AGG GCC TGG AAT AGT GCC T-3' (Metabion, Planegg-Martinsried, Germany).
**VEGF quantitation in cell culture supernatants**

We incubated 5 x 10^5 cells with AC-CM for 2 h, washed cells twice with PBS and incubated for another 16-h period. Supernatants were harvested by centrifugation (16000 g, 10 min). For the measurement of secreted VEGF, we used human VEGF Cytometric Bead Array Flex Sets (Becton Dickinson Biosciences, Heidelberg, Germany). Samples were analyzed with FACSCanto flow cytometer and quantitated using FCAP software (Becton Dickinson Biosciences, Heidelberg, Germany).

**siRNA transfections**

siRNAs against HO-1 (Hs_HMOX1_5_HP_Validated siRNA, Qiagen, Hilden, Germany), VEGFA (Hs_VEGF_5_HP_Validated siRNA, Qiagen, Hilden, Germany) or S1P1 (Ambion, Austin, TX, USA) were nucleofected into 1.5 x 10^6 primary human macrophages using Nucleofector Technology (Amaxa, Köln, Germany). HO-1 and S1P1 knockdown in comparison with siControl nontargeting Duplex #1 (Dharmacon, Lafayette, CO, USA) was controlled by Western blot analysis. The knockdown of HO-1 as well as VEGF were routinely confirmed by quantitative real-time PCR.

**Statistical analysis**

Each experiment was performed at least three times. *P*-values were calculated using the paired Student *t* test and considered significant (*) at *P* ≤ 0.05, (**) at *P* ≤ 0.01 and (***) at *P* ≤ 0.001.
RESULTS

*Apoptotic cell supernatants provoke a biphasic upregulation of HO-1*

In a first set of experiments, we analyzed HO-1 protein expression in primary human macrophages following their exposure to AC-CM. HO-1 expression showed a biphasic response. A first peak was noticed after 6 h, whereas a second peak became detectable after 24-h lasting incubations (Figure 1A). To test whether the second peak of HO-1 expression was mediated by an autocrine factor, we harvested supernatants from macrophages (МФ-СМ), previously stimulated with AC-CM, and transferred МФ-СМ to fresh, resting macrophages. Indeed not only AC-CM but also МФ-СМ caused HO-1 protein expression in primary human macrophages (Figure 1, A and B). Pronounced HO-1 expression in response to МФ-СМ was observed after 12 to 18 h, which corresponded to the second peak of HO-1 expression in response to AC-CM, seen after 24 h. Importantly, HO-1 expression was only seen in response to AC-CM, but was not elicited by NC-CM or VC-CM (Figure 1C).

Induction of HO-1 by МФ-СМ after 18 h was further corroborated by reporter assays. Using the luciferase-coupled promoter constructs phHOLUC(-4000) as well as phHOLUC(-2782), we observed significant induction of luciferase activity after treatment with МФ-СМ for 18 h (Figure 1D). No activity was noticed with the shorter luciferase construct phHOLUC(-1976). Results so far indicate that apoptotic cell supernatants enhanced not only transcription of the HO-1 promoter but also caused protein expression, with the further notion that autocrine signaling was involved.

We then investigated signal transduction pathways contributing to HO-1 expression. Early expression of HO-1, seen at 6 h in response to AC-CM, was reduced by SB203580, an inhibitor of p38 MAPK (Figure 1E). Late phase HO-1 expression at 24 h was partially attenuated by inhibiting janus kinase signaling (Figure 1F). Thus,
the early HO-1 induction in response to an AC-CM-derived soluble factor was p38-mediated, while the late and second phase of HO-1 expression was facilitated by an autocrine factor, signaling via the Jak pathway.

**S1P in AC-CM is crucial in provoking HO-1 induction**

Considering that AC release S1P (Weigert et al., 2006; Gude et al., 2008) and the further notion that S1P potentially causes HO-1 expression (Man et al., 2005), we assumed that S1P in AC-CM was responsible for HO-1 expression in macrophages. To verify this hypothesis, we stimulated primary human macrophages with authentic S1P for 24 h (Figure 2A). S1P at 100 nM and 1 µM as well as AC-CM induced HO-1 protein expression. To validate the contribution of S1P in AC-CM, we used DMS, an inhibitor of sphingosine kinases to block their activity in Jurkat cells when generating AC-CM (Weigert et al., 2006). AC-CM generated in the presence of DMS failed in inducing HO-1 expression in macrophages (Figure 2A). Supporting data pointing to the contribution of S1P in HO-1 expression came from experiments when 100 nM S1P, supplied for 24 h, induced luciferase reporter activity. S1P induced phHOLUC(-4000) and phHOLUC(-2782) but not phHOLUC(-1976) HO-1 reporter activity (Figure 2B).

Recently, it was reported that activation of S1P₁ limited the expression of pro-inflammatory cytokines (Hughes et al., 2008) and protected macrophages from apoptosis induced by the combination of TNFα and cycloheximide (Weigert et al., 2006). Intrigued by these experiments, we knocked down S1P₁ using siRNA to assess its role in HO-1 induction by AC-CM. While transfection of macrophages with nontargeting siRNA allowed HO-1 expression by AC-CM after 6 h, knockdown of S1P₁ significantly reduced the HO-1 amount (Figure 2C). As a side effect, we noticed
that AC-CM enhanced S1P₁ expression in primary human macrophages, an effect suppressed by siRNA directed against S1P₁ (Figure 2C).

**STAT1 and STAT3 provoke transcription of the HO-1 gene after AC-CM**

The induction of HO-1 after 24 h was Jak dependent (Figure 1F). Considering that HO-1 induction at 24 h was facilitated by an autocrine factor, we wished to discern whether the release or the action of the putative autocrine factor would be Jak dependent. Therefore, we analyzed signaling downstream of janus kinases, by using STAT1 and STAT3 inhibitors.

To attenuate the release of autocrine mediators, macrophages were pre-incubated for 1 h with either fludarabine, a specific inhibitor of STAT1 (Frank *et al.*, 1999), or STA-21, a specific STAT3 inhibitor (Song *et al.*, 2005), prior to addition of AC-CM. After a 2-h incubation period with AC-CM, macrophages were washed twice with PBS, followed by continuing incubations for 4 h in full medium, without the further addition of inhibitors. Thereafter MΦ-CM was harvested from these cells and incubated with fresh, unstimulated macrophages. Inhibition of STAT1 during the production of MΦ-CM by fludarabine eliminated its potential to upregulate HO-1, indicating that the production of the autocrine mediator was STAT1-dependent (Figure 3A, lane 3). In contrast, blocking STAT3 by STA-21 during the production of MΦ-CM did not reduce expression of HO-1 (Figure 3B, lane 3). Interestingly, inhibition of STAT1 or STAT3 attenuated HO-1 expression in response to MΦ-CM (Figure 3, A and B, lane 4), suggesting that the autocrine factor demands active STAT1 and STAT3 for signaling. With these initial data supporting a role of STAT1 and STAT3 in late phase (24 h) HO-1 expression by AC-CM, we screened the human HO-1 promoter for potential STAT binding sites (Figure 3C). Luciferase activity after treatment with MΦ-CM for 18 h was not induced when transfecting phHOLUC(-1976)
into macrophages (Figure 1D), thus allowing to exclude three putative STAT binding sites located within this promoter construct as candidates involved in enhanced HO-1 transcription. Concerning the two remaining potentially critical STAT binding sites in the HO-1 promoter, only oligonucleotides resembling the STAT binding site at -2361 to -2369, but not the ones containing the STAT binding site at -2436 to -2444 recruited transcription factors in EMSA analysis (Figure 3D). Supporting our observation that HO-1 expression by the autocrine factor present in MΦ-CM was inhibited by fludarabine and/or STA-21, EMSA analysis showed that transcription factor binding to the oligonucleotides spanning the STAT binding site at -2361 to -2369 was reduced when macrophages where incubated with fludarabine. Stronger inhibition was noticed when macrophages were treated with STA-21 prior to MΦ-CM stimulation, while the combined application of both STAT inhibitors reduced transcription factor binding most efficiently. These observations imply that STAT1/STAT3 heterodimer binding to the putative STAT binding site located at -2361 to -2369 at the human HO-1 promoter affects HO-1 induction following the treatment with MΦ-CM. To reinforce these results, we performed competitive EMSA analysis with unlabeled oligonucleotides specific for STAT1, STAT3 or with oligonucleotides for the putative STAT binding site at -2361 to -2369 containing a point mutation for STAT3 (Figure 3E). STAT binding to the oligonucleotides containing the STAT binding site at -2361 to -2369 was strongly reduced with increasing concentrations of the specific STAT1 and STAT3 oligonucleotides, which were added simultaneously. In contrast STAT binding was not impaired when we used oligonucleotides with the STAT3 point mutation. In addition, we performed reporter assays in primary human macrophages with the construct phHOLUC(-2782ptm). This construct contained a point mutation within the STAT binding site at -2361 to -2369 to eliminate STAT3 binding (Figure 3F). Transfection of this construct into macrophages confirmed the
results obtained by EMSA analysis, since luciferase activity elicited by MΦ-CM was significantly lower compared to transfection of the non-mutated phHOLUC(-2782).

**Late-phase HO-1 induction in macrophages requires autocrine VEGFA signaling**

With the following experiments we characterized the autocrine HO-1-inducing factor, released by macrophages, when treated with AC-CM. We degraded proteins in MΦ-CM with proteinase K digestion and subsequent denaturation. MΦ-CM, deprived by functional proteins, revealed a significantly lower ability to express HO-1 compared to untreated MΦ-CM (Figure 4A), implying that the autocrine factor might be a protein. As a candidate we proposed VEGF. Our previous results (Figure 3A) suggested that the release of the autocrine factor mediating HO-1 induction was STAT1-dependent. This corresponds to the observations of Funamoto and colleagues, who identified VEGF as a STAT1 target gene in cardiac myocytes (Funamoto et al., 2000). Furthermore, VEGFA secretion from mouse mammary epithelial cells after phagocytosis of AC was previously demonstrated (Golpon et al., 2004) and signaling of VEGF in chronic lymphocytic leukaemia B cells enhanced STAT1 and STAT3 actions (Lee et al., 2005). These observations match our data, showing that the autocrine protein factor in MΦ-CM activated STAT1/STAT3 (Figure 3, A and B). Finally, VEGF induced HO-1 in a model of hyperoxic acute lung injury (Siner et al., 2007). With this background we determined VEGF expression in macrophages in response to AC-CM. Indeed, VEGF mRNA was significantly elevated in macrophages stimulated with AC-CM for 1 h, compared to controls. Elevation of VEGF mRNA was blocked when macrophages were pre-treated with fludarabine (Figure 4B). Additionally, we measured the release of VEGF into supernatants of AC-CM treated macrophages by FACS analysis using human VEGF Cytometric Bead
Array Flex Sets (Figure 4C). AC-CM-stimulated macrophages secreted significant amounts of VEGF protein. Accompanying experiments confirmed that 100 nM authentic S1P, incubated for 1 h, enhanced VEGF mRNA expression, thus supporting the notion that S1P in AC-CM may induce VEGF (Figure 4D). The fact that HO-1 as well as VEGF expression were induced by S1P (Figures 2A and 4D), made the induction of HO-1 by autocrine VEGF signaling in primary human macrophages likely. To further scrutinize this hypothesis, we knocked down VEGF in primary human macrophages prior to their incubation with AC-CM (Figure 4E). While VEGF mRNA was induced in macrophages after treatment with AC-CM, the response was abrogated by siRNA directed towards VEGFA (Figure 4E). Next, we analyzed the expression of HO-1 protein in macrophages, which were incubated with MΦ-CM generated from VEGF knockdown or siControl transfected macrophages. When macrophages were transfected with non-targeting siRNA and incubated with AC-CM, MΦ-CM derived from these cells induced HO-1 in fresh, unstimulated cells. However, HO-1 was not induced with MΦ-CM from VEGFA knockdown macrophages (Figure 4F). These experiments suggest that VEGF mediated the autocrine induction of HO-1 after stimulation with AC-CM.

**HO-1 affects anti-inflammatory and anti-apoptotic pathways in macrophages**

HO-1 is known for its anti-apoptotic and anti-inflammatory actions (Otterbein et al., 2000; Ryter and Otterbein, 2004; Deshane et al., 2005). Having recently shown that S1P from AC-CM induced Bcl-2 and Bcl-X\textsubscript{L} in macrophages (Weigert et al., 2006), we now asked whether induction of Bcl-2 and/or Bcl-X\textsubscript{L} required HO-1. Experimentally, we knocked down HO-1 in primary human macrophages using siRNA technology. Transfection with siRNA directed against HO-1 efficiently blocked the mRNA increase of HO-1 after treatment with AC-CM for 9 h (Figure 5A). While
AC-CM upregulated Bcl-2 and Bcl-X\textsubscript{L} mRNA in macrophages transfected with non-targeting siRNA, induction was significantly diminished when macrophages were transfected with siRNA against HO-1 (Figure 5B). This suggests a role of HO-1 in contributing to the anti-apoptotic phenotype of macrophages elicited by AC-CM (Weigert \textit{et al.}, 2006).

To determine whether increased HO-1 expression also conveyed anti-inflammatory properties in our system, we analyzed the expression of three markers such as Adora A\textsubscript{2A}, IDO and HLA-DMB, which more generally are linked to anti-inflammatory responses in macrophages. While the expression of Adora A\textsubscript{2A} was enhanced in control macrophages incubated with AC-CM, knockdown of HO-1 prevented this increase (Figure 5C). However, there was no correlation between the amount of HO-1 and expression of either IDO or HLA-DMB (Figure 5, C and D). Expression of IDO mRNA was enhanced in response to AC-CM in macrophages either transfected with non-targeting siRNA or with siRNA directed against HO-1 (Figure 5C). In contrast, HLA-DMB expression was decreased following stimulation with AC-CM, which was unaffected by knockdown of HO-1 (Figure 5D). In addition, we examined whether HO-1 affected protein expression of Bcl-X\textsubscript{L} and Adora A\textsubscript{2A}. Macrophages were transfected with nontargeting siRNA or HO-1 specific siRNA and incubated with AC-CM for 16 h. Both, Bcl-X\textsubscript{L} and Adora A\textsubscript{2A} were significantly induced by AC-CM in cells transfected with non-targeting siRNA, while their expression remained equivalent to controls in macrophages with siRNA-mediated knockdown of HO-1 (Figure 5E).

HO-1 is induced in inflammatory macrophages to initiate an anti-inflammatory negative feedback loop, dependent on LPS-induced nitric oxide (NO) production (Ashino \textit{et al.}, 2008). Thus, we investigated whether NO reproduced HO-1-dependent effects on gene expression in our system. Indeed, DETA-NO induced Adora A\textsubscript{2A}, although induction was less pronounced compared to AC-CM (Figures 5, C and F).
To examine which product of the HO-1-catalyzed reaction mediated Adora A\textsubscript{2A} induction, bilirubin and the CO-releasing molecule CORM-2 were used. Both agents significantly elevated Adora A\textsubscript{2A} mRNA expression (Figure 5F). However expression was low compared to the impact of AC-CM. Interestingly, the inactivated, i.e. decomposed product of CORM-2 (iCORM-2) was without effect (Figure 5F). Considering that iron chelators showed no effect on Adora A\textsubscript{2A} mRNA expression (data not shown) excludes that ferrous iron, generated during heme degradation, is involved.

In conclusion, AC-CM caused expression of HO-1 in macrophages, which concomitantly evokes distinct anti-apoptotic as well as anti-inflammatory responses in these cells (Figure 6).
DISCUSSION

Our data suggest that AC-derived S1P induces HO-1 expression in primary human macrophages, which in turn increases the amount of anti-apoptotic proteins such as Bcl-2 or Bcl-XL and Adora A2A. The notion that authentic or AC-derived S1P induces HO-1 is in line with a report by Man and coworkers, showing that FTY720 enhanced HO-1 expression (Man et al., 2005). Human macrophages express the S1P receptor subtypes 1 to 4 (Fueller et al., 2003). Considering that activation of S1P1 attenuated the expression of pro-inflammatory cytokines in mouse macrophages (Hughes et al., 2008) in conjunction with our previous observation that S1P1 signaling in macrophages protected from apoptosis (Weigert et al., 2006) fits well with the present study, demonstrating that S1P1 provoked an increase in HO-1 expression, which in turn triggered anti-apoptotic as well as anti-inflammatory signals. Inhibitor studies revealed that in primary human macrophages p38 MAPK, a pathway well known for HO-1 induction (Wijayanti et al., 2005; Kocanova et al., 2007), facilitated S1P-evoked HO-1 expression. However, other studies have shown that p38 MAPK was also activated downstream of S1P2 (Taha et al., 2004), which might explain that siRNA-mediated knockdown of S1P1 could not completely reduce HO-1 expression after stimulation with AC-CM, with the option that residual S1P2 signaling occurred.

Our study suggests a crosstalk between S1P-signaling and VEGFA secretion from human macrophages. A connection between S1P and VEGF signaling was recently also put forward for ML-1 thyroid follicular cancer as well as human FRO anaplastic thyroid cancer cells (Balthasar et al., 2008). Furthermore, VEGF secretion from epithelial cells after phagocytosis of AC was demonstrated (Golpon et al., 2004), although neither signal cross talk between AC and epithelial cells nor signaling consequences have been fully understood. In our system there is evidence for a
soluble factor generated by AC, rather than cell-cell contacts or phagocytosis being required for VEGF secretion. A connection between S1P and VEGF signaling is highlighted, especially for models of tumor angiogenesis, proposing that tumor-derived S1P stimulates VEGF formation in endothelial cells (Milstien and Spiegel, 2006; Sabbadini, 2006). Macrophages, as cells in the tumor microenvironment, are critical players stimulating angiogenesis in a variety of human tumors, where they exhibit a pronounced M2 anti-inflammatory and anti-apoptotic phenotype. Our finding that VEGFA was not only secreted from macrophages in response to S1P, but also caused autocrine signaling to further induce HO-1, implies an important role of S1P in macrophage polarization, with particular relevance in the tumor setting. Besides mechanisms such as tumor hypoxia, the interaction of tumor-associated macrophages (TAMs) with dying tumor cells could then promote VEGFA release to stimulate tumor angiogenesis. Our unexpected observation of elevated S1P₁ expression following the treatment with AC-CM might also be attributed to autocrine VEGF, since S1P₁ expression was increased in bovine aortic endothelial cells following their exposure to authentic VEGF (Igarashi et al., 2003). VEGF expression was induced by S1P via STAT1. This finding is rather extraordinary as S1P receptor activation has not been linked to STAT signaling before. However, Src kinase activation downstream of a G-protein coupled receptor such as S1P₁ might be a missing communication link (Rivera and Olivera, 2007), although mechanisms of Src activation in response to G protein coupled receptor agonists are not fully understood (Gutkind, 2000). Src kinase activation is upstream of STAT signaling in human monocytes (Norkina et al., 2007), and one could speculate that Src kinase links S1P receptor activation to STAT activation in our system. Strikingly, in rat aortic vascular smooth muscle cells, S1P-stimulated transactivation of STAT-
coupled epidermal growth factor receptor and platelet-derived growth factor β receptor were Src-dependent (Tanimoto et al., 2004).

STAT1/STAT3 heterodimer formation was necessary for the autocrine induction of HO-1 by VEGF, which was previously observed in chronic lymphocytic leukemia B cells (Lee et al., 2005). Furthermore, STAT1 and STAT3 were involved in hyperoxia-induced gene transcription of HO-1 in RAW 264.7 macrophages (Lee et al., 2000). Activation of STATs presumably plays an important role in establishing the M2 macrophage phenotype in the tumor setting, since STAT1 is constitutively active in TAM (Biswas et al., 2006) and its enhanced signaling properties mediate T cell deletion (Kusmartsev and Gabrilovich, 2005). Also, STAT3 and STAT6 are believed to contribute to M2 macrophage polarization (Sica and Bronte, 2007).

Our work reveals that HO-1 in macrophages, besides accomplishing anti-apoptotic functions by enhancing the expression of survival promoting proteins such as Bcl-2 and Bcl-XL, also conveys an anti-inflammatory potential, exemplified by the expression of Adora A2A in response to AC-CM. The notion, that Deta-NO induced Adora A2A less pronounced than AC-CM, implies that HO-1-dependent anti-inflammatory effects were only partially mimicked by Deta-NO. This may point to induction of HO-1 by different signaling pathways and transcriptional regulators. Likely, Adora A2A is not only induced by HO-1, since we observed some expression also with a knockdown of HO-1. For NO other regulators such as Nrf2 have been suggested. Thus, an anti-inflammatory response achieved with AC-CM is rather unique and differs from a situation with only a proinflammatory stimulus such as LPS or NO to induce HO-1 expression.

According to suggestions by Zhang and colleagues, enhanced Bcl-2 and Bcl-XL expression by HO-1 could be attributed to CO (Zhang et al., 2003), as shown in a murine model of ischemia-reperfusion. Generally, several anti-apoptotic effects
attributed to HO-1 are thought to be CO-mediated (Ryter et al., 2002). This might also apply to Adora A2A, since overexpression of HO-1 as well as exposure of RAW264.7 macrophages to CO augmented Adora A2A mRNA as well as protein level (Haschemi et al., 2007). The rather marginal effect seen with CO and bilirubin in our experiments may open a further possibility that HO-1 translocates to the nucleus to bind to a transcription factor or a protein complex, resulting in enhanced transcription of Adora A2A (Lin et al., 2007). Adora A2A agonists are capable of blocking the inflammatory potential of human macrophages, such as pathogen-stimulated NO, TNF-α or IL-12 production (Hasko et al., 2007), but also promote wound healing in disease states like diabetes (Montesinos et al., 1997).

Interestingly, expression of the anti-inflammatory marker IDO was, at least in human macrophages exposed to AC-CM, HO-1-independent. Nevertheless, the principle finding that AC-CM augments expression of IDO is exciting. IDO catalyzes the rate-limiting step of tryptophane degradation. Kynurenine, one of the products of this reaction, affects proliferation as well as differentiation of helper T cells (Brusko et al., 2005; Munn and Mellor, 2007). Likely, in an inflammatory environment the presence of AC might help to promote healing, once an inflammatory stimulus is eliminated, by modulating adaptive immune responses. This phenotype pattern is further corroborated by our finding that macrophages downregulate HLA-DMB in response to AC. Although it was reported that bilirubin, a degradation product of biliverdin, suppressed MHC II expression in endothelial cells (Wu et al., 2005), we could not confirm that HLA-DMB expression was HO-1-dependent in macrophages. Despite these cell type differences, reduced expression of HLA-DMB and increased abundance of IDO favor an attenuated response of T H1 cells, which is important to progress from inflammation towards healing.
Taken together, apoptotic cell supernatants provoked alternative activation in human macrophages, characterized by up-regulation of Bcl-2, Bcl-X\textsubscript{L}, Adora \textsubscript{A2A} and IDO, but down-regulation of MHC II expression. The establishment of this anti-inflammatory phenotype was in part dependent on the induction of HO-1 by AC-derived S1P (Figure 6). Thus, targeting HO-1 and/or its downstream effectors could be a therapeutic approach to treat patients suffering from diseases linked to anti-inflammatory macrophage polarization during e.g. the late immunosuppressive phase of sepsis (Hasko and Pacher, 2008) or in cancer (Mantovani \textit{et al.}, 2002), since this would influence M2 macrophage viability as well their polarization.
ACKNOWLEDGMENTS

The authors thank Dr. Shigeru Takahashi for providing the HO-1 promoter luciferase constructs.
REFERENCES


proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 101, 890-898.


FIGURE LEGENDS

**Figure 1.** Induction of HO-1 in primary human macrophages. (A, B) Western analysis of HO-1 expression following incubations of macrophages with (A) AC-CM or (B) MΦ-CM for times as indicated. (C) HO-1 expression in macrophages treated with conditioned medium (CM) of apoptotic (AC), necrotic (NC) or viable (VC) cells for 24 h. (D) HO-1 promoter activity in primary human macrophages after transfection of individual reporter constructs and stimulation with MΦ-CM for 18 h. Firefly luciferase activity was normalized to renilla luciferase activity. Data are means ± SEM of at least four independent experiments. Asterisks mark statistically significant differences ($P \leq 0.05$). (E) HO-1 expression in primary human macrophages after incubation with AC-CM for 6 h in the presence/absence of 5 µM SB203580. (F). Treatment of macrophages with AC-CM for 24 h with 1 µM Jak inhibitor I being present. Western blots are representative for at least three individual experiments.

**Figure 2.** Apoptotic cell-derived S1P mediates HO-1 induction (A) Western analysis of HO-1 expression in primary human macrophages treated with AC-CM, S1P or DMS-AC-CM for 24 h. 20 µM DMS was used to block the release of S1P into the medium of apoptotic cells (DMS-AC-CM). (B) HO-1 promoter activity of corresponding reporter constructs in macrophages treated with 100 nM S1P for 24 h. Firefly luciferase activity normalized to renilla luciferase activity is displayed. Data represent means ± SEM of at least three independent experiments. Asterisks mark statistically significant differences ($P \leq 0.05$). (C) Macrophages were transfected with non-targeting siRNA or siRNA against S1P₁. Western analysis of S1P₁ and HO-1
was performed after 6-h treatments with AC-CM. Blots are representative for at least three individual experiments.

**Figure 3.** STAT1/STAT3 heterodimers mediate HO-1 promoter activation. Human primary macrophages were incubated for 6 h with AC-CM with or without the addition of (A) 20 µM fludarabine or (B) 10 µM STA-21. Macrophage conditioned medium (MΦ-CM) was harvested and added to fresh macrophages for 18 h with or without the addition of fludarabine (A) or STA-21 (B). Western blots are representative for at least three individual experiments. (C) Putative STAT binding sites in the human HO-1 promoter are shown. (D) EMSA analysis using 250 fmol of the oligonucleotides resembling the putative STAT binding site at -2361 to -2369 of the human HO-1 promoter. (E) Competitive EMSA analysis using 2.5 pM or 25 pM of unlabeled oligonucleotides specific for STAT1, STAT3 or oligonucleotides for the putative STAT binding site at -2361 to -2369, which contained a STAT3 point mutation (Ptm), in addition. One representative EMSA out of three is displayed. (F) HO-1 promoter activity in macrophages following transfection of the corresponding promoter constructs and stimulation with MΦ-CM for 18 h. Histograms show firefly luciferase activity normalized to renilla luciferase activity. Data represent means ± SEM of at least four independent experiments. Asterisks mark statistically significant differences ($P \leq 0.05$).

**Figure 4.** HO-1 expression in human macrophages by autocrine VEGFA signaling. (A) Macrophages were controls or treated with either MΦ-CM or de-proteinated MΦ-CM (50 µg/mL proteinase K) for 18 h. One representative Western blot out of seven is displayed. The graph shows the densitometric analysis. (B) VEGF mRNA expression after stimulation of macrophages with AC-CM or AC-CM together with 20
µM fludarabine for 1 h. (C) Quantitation of VEGF secretion by control or AC-CM-stimulated (18 h) macrophages. (D) VEGF mRNA expression in control or S1P-stimulated (100 nM, 1 h) macrophages. (E, F) Macrophages were transfected with non-targeting siRNA or siRNA against VEGFA. (E) VEGF mRNA expression in control or AC-CM-treated macrophages after 6 h. (F) Western analysis of HO-1 expression (18 h) following the treatment with MΦ-CM. One blot out of three is displayed. Graphs display mean values ± SEM of at least four independent experiments and asterisks indicate statistically significant differences (*) at $P \leq 0.05$ and (**) at $P \leq 0.01$.

**Figure 5.** Expression regulation of Bcl-2, Bcl-XL, Adora A2A, IDO and HLA-DMB. (A to E) Macrophages were controls or transfected with siRNA against HO-1 or non-targeting siRNA. Graphs show (A) mRNA expression of HO-1, (B) Bcl-2 and Bcl-XL, (C) Adora A2A and IDO and (D) HLA-DMB in macrophages following incubations with AC-CM for 9 h. Data show mean values ± SEM of at least five independent experiments. (E) Western analysis of HO-1, Bcl-XL and Adora A2A expression in macrophages after stimulation with AC-CM for 16 h. One blot out of three is shown. (F) Adora A2A mRNA expression following treatment with Deta-NO, bilirubin or CORM-2. Primary human macrophages were incubated with 500 µM Deta-NO for 9 h, 10 µM bilirubin for 1 h or 100 µM CORM-2 for 24 h. Graphs display mean values ± SEM of at least three independent experiments. Significant differences in mRNA expression are marked by asterisks (*) at $P \leq 0.05$, (**) at $P \leq 0.01$ and (***) at $P \leq 0.001$. 
**Figure 6.** Cartoon, summarizing biphasic expression of HO-1 by AC-CM in macrophages. S1P, present in AC, activated S1P₁. p38 MAPK activation and autocrine VEGF signaling induced HO-1. HO-1 contributed to alternative macrophage activation by regulating expression of Bcl-2, Bcl-X₇ as well as Adora A₂A. AC-CM also modulated expression of IDO and HLA-DMB, independent of HO-1.
Figure 2

Panel A: Western blot analysis showing the expression levels of HO-1 and Actin under different conditions:

- AC-CM: - - + - - -
- S1P [μM]: - - 0.1 1 - -
- DMS-AC-CM: - - - + +

Panel B: Bar graph showing the relative luciferase activity of the hHO-1 promoter with various deletions:

-4000, -2782, -1976, Control

Treatment with 100 nM S1P compared to untreated control.

Panel C: Western blot analysis showing the expression levels of S1P₁, HO-1, and Actin under different conditions:

- AC-CM: - + +
- siControl: - + -
- siS1P₁: - - +

Legend:
- - -
+ + +

Relative luciferase activity of the hHO-1 promoter
Figure 3

A

<table>
<thead>
<tr>
<th></th>
<th>HO-1</th>
<th>Actin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mφ-CM</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fludarabine</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Fludarabine-Mφ-CM</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th></th>
<th>HO-1</th>
<th>Actin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mφ-CM</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>STA-21</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

C

<table>
<thead>
<tr>
<th></th>
<th>STATx</th>
</tr>
</thead>
<tbody>
<tr>
<td>-2782</td>
<td></td>
</tr>
<tr>
<td>-1926</td>
<td></td>
</tr>
<tr>
<td>+1</td>
<td></td>
</tr>
</tbody>
</table>

D

E

F

<table>
<thead>
<tr>
<th></th>
<th>Mφ-CM</th>
<th>STAT1 [pM]</th>
<th>STAT3 [pM]</th>
<th>Ptm [pM]</th>
</tr>
</thead>
<tbody>
<tr>
<td>-4000</td>
<td></td>
<td>2.5</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>-2782</td>
<td></td>
<td>2.5</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>-2782pm</td>
<td></td>
<td>2.5</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>-1926</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Relative luciferase activity of hHO-1 promoter
Figure 4

(A) HO-1 vs. actin protein expression (fold of control)

(B) VEGF mRNA expression (fold of control)

(C) VEGF in supernatant [pg/ml]

(D) VEGF mRNA expression (fold of control)

(E) VEGF mRNA expression (fold of control)

(F) HO-1 and Actin Western Blots

- Mφ-CM
- Proteinase K
- AC-CM
- S1P
- Control
- Mφ-CM-siControl
- Mφ-CM-siVEGFA
Figure 5

A

HO-1 expression (fold of control)

AC-CM siControl siHO-1

*** ***

B

mRNA expression (fold of control)

AC-CM siControl siHO-1

* *

C

mRNA expression (fold of control)

AC-CM siControl siHO-1

** n.s.

D

HLA-DMA mRNA expression (fold of control)

AC-CM siControl siHO-1

*** n.s.

E

HO-1 Bcl-XL Adora A2A Actin

F

mRNA expression (fold of control)

Control Deta-NO Control Bilirubin Control CORM2 iCORM2

* *